- Home
- MCRB vs FCAP Comparison
MCRB vs FCAP Comparison
Compare MCRB & FCAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- FCAP
- Stock Information
- Founded
- MCRB 2010
- FCAP 1891
- Country
- MCRB United States
- FCAP United States
- Employees
- MCRB N/A
- FCAP N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- FCAP Savings Institutions
- Sector
- MCRB Health Care
- FCAP Finance
- Exchange
- MCRB Nasdaq
- FCAP Nasdaq
- Market Cap
- MCRB 144.6M
- FCAP 125.9M
- IPO Year
- MCRB 2015
- FCAP 1999
- Fundamental
- Price
- MCRB $20.47
- FCAP $46.35
- Analyst Decision
- MCRB Hold
- FCAP
- Analyst Count
- MCRB 4
- FCAP 0
- Target Price
- MCRB $14.33
- FCAP N/A
- AVG Volume (30 Days)
- MCRB 227.9K
- FCAP 5.0K
- Earning Date
- MCRB 11-12-2025
- FCAP 10-24-2025
- Dividend Yield
- MCRB N/A
- FCAP 2.46%
- EPS Growth
- MCRB N/A
- FCAP 9.31
- EPS
- MCRB 10.22
- FCAP 3.93
- Revenue
- MCRB N/A
- FCAP $44,673,000.00
- Revenue This Year
- MCRB N/A
- FCAP N/A
- Revenue Next Year
- MCRB N/A
- FCAP N/A
- P/E Ratio
- MCRB $2.05
- FCAP $11.85
- Revenue Growth
- MCRB N/A
- FCAP 9.48
- 52 Week Low
- MCRB $6.53
- FCAP $28.50
- 52 Week High
- MCRB $24.67
- FCAP $53.85
- Technical
- Relative Strength Index (RSI)
- MCRB 60.09
- FCAP 61.08
- Support Level
- MCRB $19.14
- FCAP $44.20
- Resistance Level
- MCRB $21.97
- FCAP $48.25
- Average True Range (ATR)
- MCRB 1.52
- FCAP 0.98
- MACD
- MCRB 0.22
- FCAP -0.04
- Stochastic Oscillator
- MCRB 80.36
- FCAP 55.92
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About FCAP First Capital Inc.
First Capital Inc is the financial holding company of First Harrison Bank. Through its subsidiary, it operates as a federally-chartered savings bank that provides banking services to individuals and business customers across locations in America. The bank offers various loans which include residential loans, construction loans, commercial real estate loans and commercial business loans. It also provides consumer loans such as home equity and second mortgage loans, and automobile and truck loans.